Niklason Laura EPresident, CEO and DirectorGrant or award · Jun 11, 2026
Congress trading in HUMA
13 transactions in HUMA reported by 2 members of Congress under the STOCK Act, most recent trade May 3, 2024. Reported transactions, not recommendations.
About Humacyte, Inc. (HUMA): stock profile, AI score and financials
Humacyte, Inc. (HUMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HUMA at 21.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,737 of 2,925 stocks — the bottom half of the AI-ranked universe. HUMA scores in the top quartile across revenue growth (90.4). Areas of concern include revenue scale (0.8) and free cash flow (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Humacyte, Inc. reports quarterly revenue of $406.0K, net income of $-36.8M, free cash flow of $-22.2M. Top institutional holders of HUMA by reported 13-F value include ANTIPODES PARTNERS Ltd, VANGUARD CAPITAL MANAGEMENT, Alyeska Investment Group, L.P., based on the most recent SEC filings. HUMA trades on the Nasdaq exchange and files with the SEC under CIK 1818382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HUMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Humacyte, Inc. directly from SEC EDGAR.